外科理论与实践 ›› 2025, Vol. 30 ›› Issue (2): 146-150.doi: 10.16139/j.1007-9610.2025.02.09
收稿日期:
2025-02-17
出版日期:
2025-03-25
发布日期:
2025-07-07
通讯作者:
蒋咏梅,E-mail: euphemia_j@163.com
LUO Xi, JIANG Yongmei(), MA Di, LU Qiuya, GU Xiaohan
Received:
2025-02-17
Online:
2025-03-25
Published:
2025-07-07
摘要:
目的:探讨肝细胞癌(HCC)病人血清微量元素及氨基酸谱的变化特点,为临床诊治提供参考依据。方法:选取本院2024年1月至2024年4月期间肝胆外科手术治疗的HCC病人104例作为研究组,另选取同期139例胆道良性疾病病人作为对照组。采用火焰原子吸收光谱法检测两组血清中铜、锌、钙、镁、铁和铅6种微量元素含量,用液相色谱串联质谱法检测21种氨基酸水平。 结果:与对照组相比,HCC组血清中铜水平明显升高(P<0.05),而锌、铁水平明显降低(P<0.05)。氨基酸谱分析发现,与对照组相比,HCC组酪氨酸、甲硫氨酸及苯丙氨酸水平升高(P<0.05),而缬氨酸、亮氨酸、异亮氨酸、谷氨酰胺及精氨酸水平降低(P<0.05)。对组间有统计学差异的微量元素和氨基酸进一步分析两者间相关性,铜与缬氨酸、亮氨酸之间存在负相关(P<0.05);而锌、铁与缬氨酸、亮氨酸及异亮氨酸之间均存在显著正相关(P<0.01)。结论:HCC病人普遍存在微量元素失衡和氨基酸代谢改变现象,且二者可能存在一定的内在联系。
中图分类号:
罗茜, 蒋咏梅, 马迪, 陆秋涯, 顾晓寒. 肝细胞癌病人血清微量元素和氨基酸变化的观察研究[J]. 外科理论与实践, 2025, 30(2): 146-150.
LUO Xi, JIANG Yongmei, MA Di, LU Qiuya, GU Xiaohan. Observation on changes of trace elements and amino acids in serum of patients with hepatocellular carcinoma[J]. Journal of Surgery Concepts & Practice, 2025, 30(2): 146-150.
表1
两组血清微量元素水平比较(x±s,μmol/L)
Trace elements | Control Group (n=139) | HCC Group (n=104) | t value | P value |
---|---|---|---|---|
Cu | 15.2 ± 2.5 | 17.1 ± 3.7 | 4.59 | <0.01 |
Zn | 92.1 ± 13.1 | 87.8 ± 11.5 | -2.71 | <0.01 |
Ca | 1.4 ± 0.1 | 1.4 ± 0.1 | 0.00 | 0.92 |
Mg | 1.5 ± 0.1 | 1.5 ± 0.1 | -0.64 | 0.52 |
Fe | 8.1 ± 0.9 | 7.7 ± 1.1 | -2.48 | <0.05 |
Pb | 16.8 ± 16.2 | 23.3 ± 62.3 | 1.04 | 0.24 |
表2
两组血清氨基酸水平比较(x±s,μmol/L)
Amino acid | Control group (n=139) | HCC group (n=104) | t value | P value |
---|---|---|---|---|
Glut | 77.2 ± 35.5 | 84.8 ± 40.5 | 1.52 | 0.12 |
Asp | 6.1 ± 1.7 | 6.5 ± 2.0 | 1.37 | 0.16 |
Asn | 46.3 ± 7.8 | 47.1 ± 10.4 | 0.72 | 0.46 |
Ser | 132.1 ± 28.9 | 134.7 ± 34.7 | 0.63 | 0.52 |
Lys | 194.4 ± 35.0 | 182.3 ± 34.5 | -2.69 | 0.08 |
Trp | 50.8 ± 9.3 | 52.4 ± 13.3 | 0.98 | 0.30 |
Phe | 63.2 ± 9.6 | 70.3 ± 13.1 | 4.68 | <0.01 |
Met | 24.8 ± 4.7 | 29.4 ± 8.2 | 5.10 | <0.01 |
Thr | 138.3 ± 36.1 | 144.6 ± 39.9 | 1.27 | 0.20 |
Leu | 134.3 ± 26.2 | 115.2 ± 28.2 | -5.39 | <0.01 |
Ile | 81.1 ± 19.1 | 72.6 ± 16.1 | -3.78 | <0.01 |
Val | 264.2 ± 49.8 | 245.6 ± 54.0 | -2.74 | <0.05 |
Arg | 63.4 ± 17.2 | 53.9 ± 18.1 | -4.16 | <0.01 |
Tyr | 64.2 ± 12.3 | 79.0 ± 23.1 | 5.94 | <0.01 |
His | 86.8 ± 11.9 | 84.0 ± 15.0 | -1.50 | 0.12 |
Orn | 111.1 ± 35.3 | 113.1 ± 30.4 | 0.49 | 0.63 |
Ala | 409.0 ± 96.1 | 396.0 ± 107.4 | -0.98 | 0.32 |
Pro | 170.5 ± 52.7 | 178.6 ± 71.2 | 0.98 | 0.31 |
Cit | 32.2 ± 9.5 | 34.8 ± 14.7 | 1.54 | 0.10 |
Gly | 229.3 ± 58.8 | 240.9 ± 64.9 | 1.43 | 0.15 |
Gln | 733.8 ± 130.8 | 640.7 ± 167.8 | -4.69 | <0.01 |
BCAA/AAA | 3.0 ± 0.5 | 1.8 ± 0.8 | -3.86 | <0.05 |
[1] | BRAY F, LAVERSANNE M, SUNG H, et al. Global cancer statistics 2022:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3):229-263. |
[2] | YANG X, TANG Z, LI J, et al. Esophagus cancer and essential trace elements[J]. Front Public Health,2022, 10:1038153 |
[3] | ISHIKAWA T. Branched-chain amino acids to tyrosine ratio value as a potential prognostic factor for hepatocellular carcinoma[J]. World J Gastroenterol, 2012, 18(17):2005-2008. |
[4] | 赵玉萍, 韩秀青, 薛书保, 等. 原发性肝癌患者血中微量元素与氨基酸浓度的变化分析[J]. 临床肝胆病杂志, 2015, 31(6):915-917. |
ZHAO Y P, HAN X Q, XUE S B, et al. Clinical analysis of blood amino acids and trace elements in patients with hepatocellular carcinoma[J]. J Clin Hepatol, 2015, 31(6):915-917. | |
[5] | 温晓静. 血浆氨基酸变化对肝癌患者的影响[J]. 临床合理用药, 2014, 7(13):126-127. |
WEN X J. Effects of plasma amino acid changes on patients with liver cancer[J]. Chin J Clin Ration Drug Use, 2014, 7(13):126-127. | |
[6] | MOSSMANN D, MÜLLER C, PARK S, et al. Arginine reprograms metabolism in liver cancer via RBM39[J]. Cell, 2023, 186(23):5068-5083.e23. |
[7] | ZHU J, THOMPSON C B. Metabolic regulation of cell growth and proliferation[J]. Nat Rev Mol Cell Biol, 2019, 20(7):436-450. |
[8] | 裴亚萍, 杨艳莉, 李娜, 等. 谷氨酰胺代谢在肿瘤治疗中的研究进展[J]. 江苏医药, 2021, 47(11):1174-1178. |
PEI Y P, YANG Y L, LI N, et al. Research progress of glutamine metabolism in tumor treatment[J]. Jiangsu Med J, 2021, 47(11):1174-1178. | |
[9] | 徐仁应, 万燕萍, 沈婉蓉, 等. 谷氨酰胺对人肝癌细胞系SMMC-7721增殖影响的体外研究[J]. 胃肠病学, 2005, 10(3):148-152. |
XU R Y, WAN Y P, SHEN W R, et al. Effects of glutamine on proliferation of human hepatoma cell line SMMC-7221 in vitro[J]. Chin J Gastroenterol, 2005, 10(3):148-152. | |
[10] | 王映翘, 杨密, 王茵, 等. 铜及铜相关蛋白在肿瘤中的研究进展[J]. 肿瘤代谢与营养电子杂志, 2022, 9(2):265-270. |
WANG Y Q, YANG M, WANG Y, et al. Research progress of copper and copper-related proteins in tumors[J]. Electron J Metab Nutr Cancer, 2022, 9(2):265-270. | |
[11] | 陈蕾洁, 刘德良, 谭玉勇. 铜死亡在肝癌中的研究进展[J]. 中南大学学报(医学版), 2023, 48(9):1368-1376. |
CHEN L J, LIU D L, TAN Y Y. Research progress in cuproptosis in liver cancer[J]. J Cent S Univ(Med Sci), 2023, 48(9):1368-1376. | |
[12] | TAWARI P E, WANG Z, NAJLAH M, et al. The cytotoxic mechanisms of disulfiram and copper(ii) in cancer cells[J]. Toxicol Res (Camb), 2015, 4(6):1439-1442. |
[13] |
LI Y, WANG L H, ZHANG H T, et al. Disulfiram combined with copper inhibits metastasis and epithelial-mesenchymal transition in hepatocellular carcinoma through the NF-κB and TGF-β pathways[J]. J Cell Mol Med, 2018, 22(1):439-451.
doi: 10.1111/jcmm.13334 pmid: 29148232 |
[14] | HIMOTO T, MASAKI T. Current trends on the involvement of zinc, copper, and selenium in the process of hepatocarcinogenesis[J]. Nutrients, 2024, 16(4):472. |
[15] | SHIGEFUKU R, IWASA M, KATAYAMA K, et al. Hypozincemia is associated with human hepatocarcinogene-sis in hepatitis C virus-related liver cirrhosis[J]. Hepatol Res, 2019, 49(10):1127-1135. |
[16] |
OZEKI I, NAKAJIMAT, SUII H, et al. Predictors of hepatocellular carcinoma after hepatitis C virus eradication following direct-acting antiviral treatment: relationship with serum zinc[J]. J Clin Biochem Nutr, 2020, 66(3):245-252.
doi: 10.3164/jcbn.19-98 pmid: 32523252 |
[17] | FANG A P, CHEN P Y, WANG X Y, et al. Serum copper and zinc levels at diagnosis and hepatocellular carcinoma survival in the Guangdong Liver Cancer Cohort[J]. Int J Cancer, 2019, 144(11):2823-2832. |
[18] | YANG D, TIAN T, LI X, et al. ZNT1 and Zn 2+ control TLR4 and PD-L1 endocytosis in macrophages to improve chemotherapy efficacy against liver tumor[J]. Hepatology, 2024, 80(2):312-329. |
[19] | 翦耀文, 熊文婧, 刘也, 等. 血清微量元素水平与肝癌相关性的Meta分析[J]. 中南医学科学杂志, 2017, 45(1):42-47. |
JIAN Y W, XIONG W J, LIU Y, et al. Meta-analysis of the correlation between trace element levels and liver cancer[J]. Med Sci J Cent S China, 2017, 45(1):42-47. | |
[20] | CHEN L, MIN J, WANG F. Copper homeostasis and cuproptosis in health and disease[J]. Signal Transduct Target Ther, 2022, 7(1):378. |
[1] | 程健珊, 张弢, 吴珺玮, 高惠峰, 陈敬贤, 孟志强. 华蟾素片联合肝动脉化疗栓塞术治疗原发性肝细胞癌的临床疗效及其影响因素分析[J]. 外科理论与实践, 2024, 29(04): 351-357. |
[2] | 施纯朝, 王葵. 2023年第2版NCCN肝细胞癌临床实践指南解读[J]. 外科理论与实践, 2024, 29(02): 99-105. |
[3] | 邵卫清, 陆录, 钦伦秀. 系统疗法改变肝癌外科的格局:机遇与挑战[J]. 外科理论与实践, 2024, 29(02): 93-98. |
[4] | 宋庆杰, 汤娟娟, 赵健全, 宋辉, 杨军. 高脂血症对乙肝相关肝细胞癌病人预后的影响[J]. 外科理论与实践, 2024, 29(02): 143-147. |
[5] | 赵磊, 钟敬涛, 孙惠川. 肝细胞癌的转化治疗中几个重要却尚无答案的问题[J]. 外科理论与实践, 2024, 29(02): 106-113. |
[6] | 胡颖涵1, 朱泽宇1, 滕 林2, 何雨石3, 邹德荣1 , 陆家瑜1. 多肽水凝胶在软骨再生工程中的应用[J]. J Shanghai Jiaotong Univ Sci, 2023, 28(4): 468-. |
[7] | 张亦凡, 鲁逸权, 郝风节, 王俊青. 多倍体肝细胞的生理功能及其病理性改变的相关疾病[J]. 外科理论与实践, 2023, 28(06): 574-579. |
[8] | 任新平, 李军建, 张杰, 詹维伟. 超声造影在肝局灶性病变诊疗中的应用进展[J]. 诊断学理论与实践, 2022, 21(06): 684-690. |
[9] | 管涛(综述), 张倜, 王鲁(审校). 肝细胞癌肺转移的潜在机制和治疗进展[J]. 外科理论与实践, 2022, 27(02): 180-184. |
[10] | 张希昊, 章馨允, 曹曼卿, 张金梁, 王华琪, 张苏, 付周, 王鲁, 张倜. 肝细胞癌的抗血管生成免疫联合介入治疗:肝动脉灌注化疗与化疗栓塞疗效的比较[J]. 外科理论与实践, 2022, 27(02): 152-157. |
[11] | 孙惠川. 肝细胞癌转化治疗的现状与展望[J]. 外科理论与实践, 2022, 27(02): 134-138. |
[12] | 马婧嶔, 杨敏捷, 颜志平. 精细TACE的治疗目标与栓塞终点[J]. 外科理论与实践, 2022, 27(02): 131-133. |
[13] | 冯浩, 吕子成, 夏强. 肝癌肝移植全过程管理及治疗进展[J]. 外科理论与实践, 2022, 27(02): 119-122. |
[14] | 黄纪伟, 邱国腾, 曾勇. 肝细胞癌外科治疗进展[J]. 外科理论与实践, 2022, 27(02): 113-118. |
[15] | 吴城孝, 方婕, 周霁川, 肖永胜, 张晓光. 基于TCGA数据库肝细胞癌microRNA-324-5p表达与预后危险因素分析[J]. 外科理论与实践, 2021, 26(03): 249-253. |
阅读次数 | ||||||
全文 |
|
|||||
摘要 |
|
|||||